KRAS and cancer: Thereby, cancers with KRAS mutations experience constitutively elevated signaling via KRAS effector pathways such as activation of the phosphatidylinositol 3 kinase (PI3) kinase pathway via direct interaction of KRAS with the catalytic PI3K subunit p110α62.